Drug intelligence / Profile preview

TP05 Coating D

Development stage: Unknown
Lead developer: Tillotts Pharma
Modality: Small Molecules
Administration: Oral

Overview

TP05 Coating D is a specific coating formulation of TP05 that was investigated in clinical trials for ulcerative colitis. It was studied alongside other coating formulations (TP05 Coating E and TP05 Coating H) in a pharmaco-scintigraphic study to evaluate gastrointestinal transit and release profiles in healthy subjects and patients with active ulcerative colitis.

Targets

15-LOX (Lysyl Oxidase)PPARG (Peroxisome proliferator-activated receptor gamma)COX

Beyond the preview

Go deeper on TP05 Coating D.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TP05 Coating D.

Explore the full profile